Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Niraparib for HRD-positive Advanced Ovarian Cancer

FDA also approved the Myriad myChoice CDx test for determination of tumour HRD status to select patients for niraparib
28 Oct 2019
Anticancer agents & Biologic therapy;  Gynaecologic malignancies;  Personalised medicine

On 23 October 2019, the US Food and Drug Administration (FDA) approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.

Efficacy was investigated in 98 patients with advanced ovarian cancer with HRD-positive tumours in the single-arm QUADRA trial (NCT02354586). Patients were treated with three or more prior lines of chemotherapy. Patients with prior exposure to PARP inhibitors were excluded. Patients without BRCA mutations must have progressed at least six months after the last dose of platinum-based therapy. HRD-positive status was determined using the Myriad myChoice CDx as either tumour BRCA mutated (tBRCAm) (n=63) and/or a genomic instability score (GIS) ≥ 42 (n=35). All patients received 300 mg of niraparib once daily until disease progression or unacceptable toxicity 

The primary efficacy outcome measures were objective response rate (ORR) and duration of response (DoR), as assessed by the investigator using RECIST v1.1. In the 98 patients in the HRD-positive cohort, ORR was 24% (95% CI: 16, 34). All were partial responses. Estimated median DoR was 8.3 months (95% CI: 6.5, not estimable).

For patients with tBRCAm ovarian cancer, ORR was 39% (7/18; 95% CI: 17, 64) in patients with platinum-sensitive disease, 29% (6/21; 95% CI: 11, 52) in those with platinum-resistant disease, and 19% (3/16; 95% CI: 4, 46) in patients with platinum-refractory disease.

Adverse reactions led to dose reduction or interruption in 73% of patients receiving niraparib in QUADRA. The most common adverse reactions (>5%) resulting in dose reduction or interruption were thrombocytopenia (40%), anaemia (21%), neutropenia (11%), nausea (13%), vomiting (11%), fatigue (9%), and abdominal pain (5%).

The recommended niraparib dose is 300 mg taken once daily with or without food. Patients should be selected for therapy based on an FDA-approved companion diagnostic for niraparib.

Full prescribing information for ZEJULA is available here.

The FDA also approved the Myriad myChoice CDx test for determination of tumour HRD status to select patients for niraparib. Information on the FDA-approved test for the detection of deleterious or suspected deleterious BRCA mutation and/or genomic instability for this indication is available here.

FDA granted this application priority review.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 28 Oct 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.